DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow DXCM
DexCom, Inc. (DXCM) EBITDA
DexCom, Inc.'s EBITDA for fiscal 2025 was $1.2B, up 42.3% from $817.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Over the past ten years it has ranged from −$157.2M (fiscal 2018) to $1.2B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 7 consecutive fiscal years. DexCom, Inc. ranks 11th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.2B | 42.30% |
| FY2024 | $817.7M | 4.34% |
| FY2023 | $783.7M | 43.25% |
| FY2022 | $547.1M | 48.75% |
| FY2021 | $367.8M | 0.33% |
| FY2020 | $366.6M | 91.94% |
| FY2019 | $191.0M | — |
| FY2018 | −$157.2M | — |
| FY2017 | −$26.4M | — |
| FY2016 | −$48.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $386.5M | 19.88% |
| Mar 2026 | $322.4M | (16.95%) |
| Dec 2025 | $388.2M | 26.82% |
| Sep 2025 | $306.1M | 11.07% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| BSX Boston Scientific Corporation compare | $5.6B |
| PHG Koninklijke Philips N.V. compare | $3.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.3B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $2.3B |
| STE STERIS plc compare | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.6B |
| DXCM DexCom, Inc. | $1.4B |
| PEN Penumbra, Inc. compare | $204.5M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement